Barcelona, 2017-05-18 - NBE-Therapeutics invited to present at the 2nd Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics

Ulf Grawunder, CEO of NBE-Therapeutics, will present an update on NBE-Therapeutics' ADC development activities at the 2nd Annual Antibody Drug Conjugates (ADC) Summit, Barcelona, Spain

Read more

London, 2017-05-15 - NBE-Therapeutics will present at the 2nd Annual Advances in Immuno-Oncology Congress, London, U.K.

Ulf Grawunder, CEO of NBE-Therapeutics, invited to present an update on NBE-Therapeutics' ADC development activities at the 2nd Annual Advances in Immuno-Oncology Congress, London, U.K.

Read more

Boston, MA, USA, 2017-05-02 - NBE-Therapeutics to present update on R&D activities at 2017-PEGS conference

Roger R. Beerli, CSO of NBE-Therapeutics, will present an update on the company's Transpo-mAb antibody discovery activities

Read more

HsinChu, Taiwan, 2017-04-06 - NBE-Therapeutics is invited to present at the 2017 International Advanced Drug Delivery Symposium (IADDS), Taiwan

Ulf Grawunder, CEO of NBE-Therapeutics, has been invited as a keynote speaker at the 2017 IADDS conference at the Industrial Technology Research Institute (ITRI), Taiwan

Read more

Washington, D.C., USA, 2017-04-02 - NBE-Therapeutics to present at the AACR Annual Meeting 2017

Roger R. Beerli, CSO of NBE-Therapeutics, to present an update on NBE-Therapeutics' ADC development activities

Read more

next >